Contemporary threat of influenza virus infection;Współczesne zagrozenie wirusem grypy

Polski Merkuriusz Lekarski

Volumn 28, Issue 163, 2010, Pages 5-7

  Ptusa, T ^a  

^a CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF NATIONAL DEFENSE   (Poland)

Author keywords

Swine origin influenza virus

Indexed keywords

INFLUENZA VACCINE; SIALIDASE;

ARTICLE; DRUG ANTAGONISM; EPIDEMIC; HEALTH; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; POLAND; SEASON;

DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; POLAND; SEASONS; WORLD HEALTH;

EID: 76849097285     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int., 2006; 15/81: 21-20.
2. Blank P.R., Schwenkglenks M., Szucs T.D.: Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J. Infect., 2009; 58: 446-58.
3. Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A/H1N1 virus after vaccination with seasonal influenza vaccine. Morb. Mortal. Wkly Rep., 2009; 58/21: 521-4.
4. Centers for Disease Control and Prevention. Update: novel influenza A/H1N1 virus infection - Mexico, March-May, 2009. Morb. Mortal. Wkly Rep., 2009; 58/21: 585-9.
5. Crum-Cianfone N.F., Blair P.J., Faix D. et al.: Clinical and epidemiologic characteristics patients an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin. Infect. Dis., 2009; Nov 13 (Epub adead of print).
6. Fleming D.M., Elliot A.J.: The impact of influenza on the health, and health care utilization of elderly people. Vaccine, 2005; 23 suppl.1: S1-9.
7. Grennbaum J.A., Kotturi M.F., Kim Y. al.: Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc. Natl. Acad. Sci. USA, 2009; Nov 16 (Epub ahead of print).
8. Kawai N., Ikematsu H., Hiritsu N. et al.: Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: A Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin. Infect. Dis., 2009; Nov 13(Epub ahead of print).
9. Mereckiene J., Cotter S., Nicoll A. et al.: VENICE Project Gatekeepers Group. National seasonal influenza vaccination survey in Europe, 2008, Euro Surveill. 2008; 13(43). pii: 19017.
10. Nicholson K.G., Wood J.M., Zambon M.: Influenza. Lancet, 2003; 362: 1733-45.
11. Okomo-Adhiambo M., Nguyen H.T., Sleeman K. et al.: Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res., 2009; Nov.13 (Epub ahead of print).
12. Uhnoo I., Linde A., Pauksens K. et al.: Treatment and prevention of influenza: Swedish recommendations. Scand. J. Infect. Dis., 2003; 35/1: 3-11.
13. Weber S.A., Ostermann A., Pohl C.: Fulminant, life-threatening influenza A/H1N1 virus infection. Dtsch. Med. Wochenschr., 2009; 134(48): 2447-50.
14. Wong S.S., Yuen K.Y.: Avian influenza virus infections in humans. Chest, 2006; 129/1: 156-68.
15. Wutzler P., Kossow K.D., Lode H. et al.: Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J. Clin. Virol., 2004; 31/2: 84-91.